OPRM1 and Alzheimer disease: These changes in MOR signalling may contribute to the dysregulated striatal dopaminergic signalling shown in AD (Martinez et al., 2005) and GD (Boileau et al., 2014) and be a potential target for opioid receptor antagonist treatment.